Chronic Idiopathic UrticariaPhase 3NCT02166151
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
A Phase 3 study testing Omalizimab in people with Chronic Idiopathic Urticaria, run by Rabin Medical Center at 1 site in Israel.
Trial summary
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Chronic Idiopathic Urticaria
- What is being tested?
- Omalizimab
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteIsrael
- Study dates
- Jul 2014to Jun 2016
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosis of chronic idiopathic urticaria for 3 months
- failure on treatment with at least 2 antihistamins and systemic corticosteroids or cyclosporin
Who cannot join
- physical or cholinergic urticaria
- past treatment in Omalizumab i nprevious year
- parasitic infection
- malignancy in last 5 years
- known sensitivity to Omalizumab
Trial locations and contacts
1 site in 1 country.
Israel1 site
Rabin Medical Center
Petah Tikva, Israel, 49100
Michael David, Prof, 972-3-9377435, mdavid@clalit.org.il
Michael David, Prof
About this study
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.
- Conditions
- Chronic Idiopathic Urticaria
- Being tested
- Omalizimab
- Medical subject headings
- Chronic Urticaria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OmalizimabDrug
Also called Xolair
Omalizimab 150 mg S.C. once a month for consecutive 3 months
| Study group | Role | What they receive |
|---|---|---|
| Omalizumab | Experimental | Omalizimab 150 mg S.C. once a month for consecutive 3 months Receives: Drug: Omalizimab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants with ≥ 50% Decrease in Urticaria Activity Score (UAS)
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2014 (estimated)
- Study startJul 2014
- Primary completionJun 2016 (estimated)
- Study completionJun 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Idiopathic UrticariaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rabin Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michael David, Rabin Medical Center
- Investigators
- Michael David, Prof, Principal investigator, Rabin Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02166151
- Sponsor's protocol ID
- 0550-31 -RMC
- Status last verified
- Jun 2014
- First submitted
- 28 May 2014
- Last updated
- 18 Jun 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
- ClinicalTrials.gov ID
- NCT02166151
- Acronym / sponsor ID
- 0550-31 -RMC
- Conditions
- Chronic Idiopathic Urticaria
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Rabin Medical CenterUniversity, hospital or other
- Study start
- Jul 2014
- Primary completion
- Jun 2016 (estimated)
- Study completion
- Jun 2016 (estimated)
- First posted
- 18 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Omalizumab | Experimental | Drug: OmalizimabOmalizimab 150 mg S.C. once a month for consecutive 3 months |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- diagnosis of chronic idiopathic urticaria for 3 months
- failure on treatment with at least 2 antihistamins and systemic corticosteroids or cyclosporin
Key exclusion criteria (5 listed)
- physical or cholinergic urticaria
- past treatment in Omalizumab i nprevious year
- parasitic infection
- malignancy in last 5 years
- known sensitivity to Omalizumab
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OmalizimabAlso: XolairOmalizimab 150 mg S.C. once a month for consecutive 3 months | Drug | Omalizumab |
Primary outcome
Percentage of Participants with ≥ 50% Decrease in Urticaria Activity Score (UAS)
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2014.
Related trials for Chronic Idiopathic Urticaria
RecruitingPhase 2
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Not yet recruitingPhase 2
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
Chronic Urticaria, Idiopathic
Not yet recruitingPhase 3
Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.
Chronic Idiopathic Urticaria
RecruitingPhase 4
Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria, Chronic Urticaria, Idiopathic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael David, Prof principal investigator
Rabin Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Omalizimab in people with Chronic Idiopathic Urticaria, run by Rabin Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants with ≥ 50% Decrease in Urticaria Activity Score (UAS) (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2014; AzTrials last refreshed its copy on 8 Nov 2026.